Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 5.45 SEK -2.68%
Market Cap: kr1.4B

Operating Margin

45.9%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
45.9%
=
Operating Income
kr141.8m
/
Revenue
kr308.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
45.9%
=
Operating Income
kr141.8m
/
Revenue
kr308.7m

Peer Comparison

Country Company Market Cap Operating
Margin
SE
Cantargia AB
STO:CANTA
1.4B SEK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 90% of companies in Sweden
Percentile
90th
Based on 2 047 companies
90th percentile
45.9%
Low
-2 025 693.8% — -1.8%
Typical Range
-1.8% — 12.5%
High
12.5% — 10 459.2%
Distribution Statistics
Sweden
Min -2 025 693.8%
30th Percentile -1.8%
Median 6%
70th Percentile 12.5%
Max 10 459.2%

Cantargia AB
Glance View

Market Cap
1.4B SEK
Industry
Biotechnology

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

CANTA Intrinsic Value
2.32 SEK
Overvaluation 57%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
45.9%
=
Operating Income
kr141.8m
/
Revenue
kr308.7m
What is Cantargia AB's current Operating Margin?

The current Operating Margin for Cantargia AB is 45.9%, which is in line with its 3-year median of 45.9%.

How has Operating Margin changed over time?

Over the last 0 months, Cantargia AB’s Operating Margin has decreased from 45.9% to 45.9%. During this period, it reached a low of 45.9% on Oct 30, 2025 and a high of 45.9% on Oct 30, 2025.

Back to Top